Kim Margolin, MD; Przemyslaw Twardowski, MD; Leland Foshag, MD; Parvin Peddi, MD; Santosh Kesari, MD; Emma Chacon, RN, Discuss the Impact of Clinical Trials and Research.
Clinical trials help physicians and scientists evaluate new approaches to cancer prevention, diagnosis, and treatment. For International Clinical Trials Day, Saint John’s Cancer Institute brought together medical oncologists, surgical oncologists, and clinical research professionals to explain why these studies matter, how patients participate, and what research may contribute to future cancer care. Their original 2023 interviews provide firsthand perspectives from several specialties, including melanoma, breast cancer, brain tumors, and urologic oncology.
At Providence Saint John’s Health Center, clinical research connects investigators, treating physicians, research nurses, and coordinators who work together to evaluate investigational treatments under established study protocols.
For some patients, clinical trials offer an opportunity to consider treatments being evaluated alongside or instead of established approaches. However, investigational therapies may not provide a benefit, can cause side effects, and are not appropriate for everyone.
Przemyslaw Twardowski, MD, a medical oncologist whose research includes genitourinary cancers, described one important role for clinical trials:
“clinical trials are particularly valuable in patients who may have very advanced, heavily pretreated cancer, where there is no available effective standard of care. Promising experimental therapies have significant value in those circumstances.”
While trials can be especially important when treatment options are limited, many studies investigate therapies at earlier stages of care. Patients should discuss potential research opportunities with their oncology team according to their specific diagnosis and medical circumstances.
The History of Clinical Research at Saint John’s Cancer Institute
Clinical investigation has been part of Saint John’s Cancer Institute’s history since its development as the John Wayne Cancer Institute under Donald L. Morton, MD.
Dr. Morton’s research included melanoma immunology, cancer vaccines, and the development and clinical evaluation of sentinel lymph node biopsy.
Leland Foshag, MD, reflected on that history in the original interview:
This institute was founded on the basis of clinical trials, back more than 30 years ago, beginning with a variety of melanoma vaccine trials under the direction of Donald L. Morton. He developed the technique of sentinel lymph node procedure which was validated and has been completely shown to change the surgical management of primary melanomas.
– Dr. Leland Foshag
The historical development of sentinel lymph node biopsy illustrates how clinical research can change the evaluation and treatment of certain cancers after sufficient evidence establishes a technique’s value.
Clinical trials remain one of the principal methods by which physicians evaluate whether a new intervention is safe, effective, and appropriate for broader clinical use.
Learn more about Donald L. Morton, MD, and his contributions to cancer research.
What Are Clinical Trials and Why Are They Important?
Clinical trials are research studies involving people that are designed to answer specific medical or scientific questions.
In oncology, trials may investigate new drugs, immunotherapies, targeted treatments, surgical approaches, radiation techniques, diagnostic methods, supportive care, or cancer prevention strategies.
Clinical trials are conducted according to research protocols that establish eligibility criteria, treatment or evaluation procedures, monitoring requirements, and methods for collecting and interpreting data.
Before beginning, studies undergo applicable scientific, ethical, and regulatory review. These safeguards are designed to protect participants, but they cannot eliminate all risks or guarantee that the investigational intervention will work.

Parvin Peddi, MD, a medical oncologist whose work includes breast cancer research, described how investigators evaluate potential therapies through successive stages of study:
“Whenever a new drug is studied in the lab, the first thing you need is to actually test it out. First in a small number of patients, just to see that it is safe, and make sure that it really is starting to work. Then, to see in a bigger trial, whether it beats what’s on the market. This is how we have made stride after stride in all cancers; how we made cancers that are incurable to curable…The field of breast cancer has really benefited.” says Dr. Parvin Peddi.
Her comments explain the importance of systematic clinical evaluation. The exact sequence varies according to the treatment, disease, and study design, and not every experimental treatment advances through all research phases.
Santosh Kesari, MD, whose clinical research has included brain tumors and neuro-oncology, emphasized the biological differences between patients and their cancers:
What we are learning is that every person is unique. The tumors are different, even though they are called the same thing.
– Santosh Kesari, MD
Differences in tumor genetics, disease stage, previous treatment, and overall health can influence both treatment decisions and eligibility for particular clinical studies.
Understanding the Four Phases of Clinical Research
Treatment trials are often described by phases, although not every clinical study uses the same structure. Some combine phases, and many diagnostic, surgical, or observational studies are organized differently.
Phase I: Initial Safety, Dosage, and Tolerability
Phase I studies often involve relatively small groups of participants and investigate safety, side effects, how a drug behaves in the body, and an appropriate dose or treatment schedule.
Some Phase I oncology trials are first-in-human studies. Others evaluate new combinations or uses of treatments that have already been studied in people.
Participants may have advanced cancers for which established treatment options are limited, but eligibility varies by study.
Phase II: Evaluating Activity and Continued Safety
Phase II trials usually involve larger groups and examine whether an investigational treatment shows evidence of activity against a particular disease.
Researchers continue to monitor safety and may study outcomes such as tumor response, disease control, or other specified endpoints.
Positive Phase II findings do not automatically establish that a treatment is more effective than an existing standard of care.
Phase III: Comparing Treatments
Phase III trials often compare a new treatment strategy with an established treatment, another intervention, or an appropriate control group.
These studies may involve participants at several medical institutions and are designed to evaluate effectiveness and safety using prespecified outcomes.
Results may contribute evidence used in regulatory decisions and clinical practice guidelines, although a successful Phase III trial does not guarantee approval or adoption for every patient.
Phase IV: Research After Regulatory Approval
Phase IV studies are generally conducted after a treatment receives regulatory approval. They may evaluate long-term safety, effectiveness in broader populations, or additional questions arising during clinical use.
Phase IV research can identify uncommon side effects and improve understanding of how treatments perform outside the original clinical trial population.
Not all clinical trials involve new drugs, and the phases described above are not a measure of how appropriate or beneficial a particular study will be for an individual patient.
Watch Saint John’s Cancer Researchers Explain Clinical Trials
In this original International Clinical Trials Day interview, physicians and clinical research personnel discuss why clinical trials are important, what participants should understand, and how research may contribute to future treatment options.
The video features Kim Margolin, MD; Santosh Kesari, MD; Przemyslaw Twardowski, MD; Parvin Peddi, MD; Leland Foshag, MD; and Emma Chacon, RN.
The interviews were recorded in 2023. Specific physician responsibilities, available studies, and research programs may have changed since that time.
Medical and Surgical Oncology Experts Discuss the Importance of Clinical Trials
Drs. Kim Margolin, Santosh Kesari, Przemyslaw Twardowski, Parvin Peddi, and Leland Foshag, together with Emma Chacon, RN, discuss clinical research and patient participation. Original 2023 interview.
How Can Patients Participate in a Clinical Trial?
The decision to consider a clinical trial usually begins with a discussion between the patient and their treating physician.
A clinical research team can then help determine whether an available study addresses the patient’s diagnosis and circumstances.
Each study has eligibility criteria designed to answer its research question and protect participants. These requirements may involve cancer type, stage, molecular findings, previous treatments, overall health, laboratory results, and other factors.
Step 1: Discuss Research Options With a Physician
Patients can ask their oncologist whether an appropriate clinical trial is available at their treatment center or another participating institution.
The physician can explain how an investigational approach compares with established treatment options and whether additional evaluation may be useful.
Clinical trials should be considered according to medical circumstances rather than automatically reserved until every other treatment has failed.
Step 2: Review Study Eligibility and Informed Consent
When a potentially appropriate study is identified, research personnel explain its purpose, procedures, expected duration, potential risks, possible benefits, and available alternatives.
Emma Chacon, a research nurse at Saint John’s Cancer Institute during the original interview, emphasized that participation is a choice:
“With clinical trials, it’s not anything that is mandatory, it’s completely voluntary. We’re seeking to give people treatment options if they would like them. For a clinical trial, we have to go through a rigorous process of making sure we are finding the right patient. That means we need to assess them,” says Emma Chacon, a research nurse at Saint John’s Cancer Institute.
Informed consent is an ongoing process, not simply signing a form. Patients should have opportunities to ask questions, understand alternatives, and decide whether participation aligns with their goals.
Signing a consent form does not necessarily mean the patient has passed all screening requirements or has been enrolled to receive the study intervention.
Step 3: Complete Study-Specific Screening

After appropriate consent is obtained, the research team may coordinate tests to determine whether the patient meets the study’s requirements.
Depending on the protocol, screening may involve:
- Reviewing the cancer diagnosis and treatment history.
- Confirming pathology, disease stage, or molecular biomarkers.
- Performing laboratory tests or diagnostic imaging.
- Evaluating other medical conditions and medications.
- Confirming the patient’s ability to complete required visits and monitoring.
Even after screening, some patients will not qualify for a particular study. The research team and treating physician can discuss other appropriate options.
Step 4: Participate and Receive Study Monitoring
Patients who enroll follow a treatment or observation plan established by the protocol.
Clinical trials include scheduled examinations and data collection to evaluate safety and study outcomes. The frequency of visits and tests varies, and some studies require more appointments than conventional care.
Research nurses and coordinators help explain the schedule, monitor study-related concerns, and communicate with the principal investigator and treating team.
Clinical trial participation does not guarantee more effective treatment or better outcomes, and additional visits or testing may create practical burdens.
Step 5: Understand the Right to Withdraw
Participation in a clinical trial is voluntary. Patients can choose not to enroll or may withdraw from a study without losing access to otherwise available medical care.
Before withdrawing, patients should discuss how study treatment will be stopped safely and what follow-up medical care may be appropriate.
In the original interview, Emma Chacon explained:
“it’s something you can withdraw from at any time, it’s not a commitment that is for the rest of your life. We want to make sure we are giving you what you want. Your decision about your body should be informed.”
These principles are central to research ethics and patient autonomy.
Clinical Trials Are Not Necessarily a Last Resort
Some patients and physicians associate clinical trials primarily with advanced cancers for which standard treatments are no longer effective.
Although these studies are important, clinical research also includes investigations conducted before surgery, after treatment, during first-line therapy, or among patients at increased risk of developing cancer.
During the original interview, Bethany Wendel, then Senior Manager of Clinical Research, discussed the importance of considering research earlier in treatment planning.
“Community physicians tend to look to clinical trials as a last resort for their patients,” Bethany Wendel, Senior Manager of Clinical Research states. She continues, “in the face of alternative treatments, as an example, immunotherapy, clinical trials are often the best first options for patients who are looking to avoid the standard chemotherapy for their disease.”
Dr. Peddi also encouraged patients to raise the subject directly with their treating physicians:
“as a patient, you should always ask your doctor, can I have access to a clinical trial? I understand this is the standard, but can something else be tried that could be better than this? It’s critical that patients are offered [clinical trials] and discuss with their doctors what trial they can enroll in… and we have many here that are open at Saint John’s.”
These statements express the physicians’ perspectives during the 2023 interviews. Clinical trials should not automatically be assumed to be better than established treatment, and participation in a study does not necessarily mean standard chemotherapy or other conventional therapies can be avoided.
The appropriate choice depends on the trial’s design, the current evidence, and each patient’s diagnosis and treatment goals.
Improving Representation and Access in Clinical Research
Clinical research is most informative when study participants reflect the populations who may eventually use the treatments being evaluated.
Historically, some racial, ethnic, geographic, socioeconomic, and other patient populations have been underrepresented in clinical trials.
Barriers may include transportation, travel expenses, time away from work, limited information about available studies, language differences, and concerns about research participation.
Improving trial access requires attention to these practical and institutional barriers.
Saint John’s Health Center previously supported a Stand Up To Cancer initiative addressing disparities in colorectal cancer screening and research. Anton Bilchik, MD, PhD, participated in the related multidisciplinary research effort.
The initiative illustrates how cancer research can extend beyond investigating treatments to addressing inequities in screening, diagnosis, and access to medical services.
Learn more about the original Stand Up To Cancer colorectal cancer disparities initiative.
Understanding the Uncertainty of Clinical Research

One of the most important considerations for patients is understanding that the outcome of an investigational treatment cannot be known in advance.
Some participants experience a response to treatment, while others may not benefit or may experience side effects. Clinical studies are designed to help investigators evaluate these outcomes systematically.
Dr. Kesari explained that patients who cannot enter a particular study may still have other appropriate treatment options:
“In many cases, patients may not qualify for trials for one reason or another, and in those situations, we still have options. We have the latest in molecular profiling to come up with innovative treatment options for patients when they don’t qualify,”
Molecular profiling can sometimes help physicians identify established targeted therapies or determine whether other studies may be appropriate. Not every cancer has an actionable biomarker, and testing does not guarantee access to an effective treatment.
Dr. Kesari also described the uncertainty that is inherent to clinical investigation:
Even in trials that don’t work, there are a subset of patients that do respond very well. And as we open more trials, the more options we give patients, the more chances the patient has to respond to something. Until we do the trial, we don’t’ know what the benefit is. I think that is the exciting and the anxiety provoking part of any clinical trial for the doctor as well as the patient, because of the uncertainty.
– Santosh Kesari, MD
Clinical research is essential precisely because the benefits and risks of an intervention may not yet be fully understood.
Clinical Research Across Cancer Specialties
The original 2023 interviews highlighted research involving melanoma, brain tumors, genitourinary cancers, and breast cancer.
These discussions provide useful examples of the types of questions investigated through clinical trials. However, the specific studies mentioned in the original interviews should be understood as historical rather than assumed to remain open for enrollment.
Brain Tumors and Neuro-Oncology
Dr. Kesari discussed the importance of researching new treatments for brain tumors, including glioblastoma and other cancers affecting the central nervous system.
Investigations discussed at the time included tumor-directed vaccine approaches, intraoperative radiation, and treatments for newly diagnosed or recurrent brain tumors.
“Clinical trials are very important, especially in the area of brain cancer, because the need is so great, ” says Dr. Kesari.
Research involving brain tumors continues to investigate drug therapies, immunotherapy, radiation strategies, molecular characteristics, and other approaches.
Current study eligibility and enrollment should be checked through the Saint John’s Clinical Trials Directory.
Melanoma and Other Skin Cancers
Kim Margolin, MD, discussed the importance of immunotherapy research in melanoma and other skin cancers.
Her original interview described studies involving immune-based treatments, imaging approaches, and therapies for patients whose melanoma had not responded adequately to previous treatment.
“Most of our clinical trials in melanoma, and other skin cancers, are based on some form of immunotherapy,” says Dr. Kim Margolin, medical oncology director for the melanoma and skin cancer program at SJCI.
She also described the scientific interest in approaches designed to stimulate immune responses:
“acts to cause the body to make its own antigens and then sensitize the immune cells against those antigens. Very similar to any other vaccine. However, when it’s given to patients who are at high risk of developing a cancer, or those who’ve had the cancer removed and have no more than a tiny trace of the tumor in the body, those vaccines may be far more powerful.”
Different immunotherapies work through different mechanisms. Cancer vaccines remain an area of research, while several other forms of immunotherapy are established treatments for particular melanoma diagnoses.
The availability of specific trials changes as studies open, complete enrollment, or close.
Explore the Melanoma and Cutaneous Oncology Program for disease and treatment information.
Urology and Genitourinary Cancers
Dr. Twardowski discussed clinical research involving prostate and other genitourinary cancers.
“The clinical trial is really my main focus, as far as clinical research. It’s the most exciting part of oncology when you can participate in the process of development of new exciting compounds and push the field forward. This is the only mechanism in existence that allows the development and ultimately approval of new drugs for cancer, for our patients,” says Dr. Twardowski.
Among the studies discussed in 2023 were investigations involving white button mushroom extract in prostate cancer and experimental agents added to established treatments.
These examples should not be interpreted as currently recruiting trials or as proof that the investigational approaches are effective.
Learn more about the Urology and Urologic Oncology Program and current clinical research opportunities.
Breast Cancer Clinical Research
Dr. Peddi discussed ongoing breast cancer trials and the importance of considering research across different treatment settings.
“We are enrolled in multiple breast cancer trials right now,” says Dr. Parvin Peddi, principal investigator.
Her original interview referenced studies involving breast imaging and investigational immunotherapy strategies, including research for patients with triple-negative breast cancer.
These were examples of studies discussed in 2023. Patients should consult the current research directory to determine which studies are available and whether they meet eligibility criteria.
Dr. Peddi expressed her enthusiasm for research participation:
You don’t lose anything and have everything to gain by enrolling in a clinical study.
– Parvin Peddi, MD
Her statement reflects the encouragement she offered in the original interview. However, every clinical trial has potential risks, burdens, and uncertainties, and there is no guarantee of benefit. Patients should evaluate those considerations through the informed consent process before deciding whether to participate.
Explore the Breast Surgery and Oncology Program and current clinical trials.
Gynecologic and Other Cancer Research
The original article also discussed potential expansion of clinical research involving gynecologic cancers and other specialties.
Because new studies open and close over time, a statement about future plans in 2023 does not establish that a particular trial is currently enrolling.
Patients with ovarian, uterine, cervical, or other gynecologic cancers can discuss research opportunities with their treating gynecologic oncologist.
Learn more about the Gynecologic Oncology Program and use the current trials directory to review available studies.
Watch Mark Perzley Describe His Clinical Trial Experience
Alongside the physician and research staff interviews, the original article includes an interview with Mark Perzley about his personal experience participating in a clinical trial.
Patient accounts can help others understand the practical and emotional considerations involved in research participation. However, an individual’s experience cannot predict how another patient will respond to an investigational treatment.
Mark Perzley Discusses His Experience Participating in a Clinical Trial
Mark Perzley shares his personal experience with clinical research during an interview with Saint John’s Cancer Institute staff.
Where Can Patients Find Current Clinical Trials?
Clinical trial availability changes as studies begin recruiting, complete enrollment, or reach their planned endpoints.
Rather than relying on a historical list of studies, patients and referring physicians should use current clinical trial resources.
- Saint John’s Cancer Institute — Active Clinical Trials: Search available studies by cancer program, treatment area, and other information.
- ClinicalTrials.gov: Search a United States government database of clinical research studies by condition, location, enrollment status, and study characteristics.
- National Cancer Institute — Clinical Trials Search: Find cancer-related research studies and educational information about participation.
- FDA — Clinical Trial Participation: Learn about research safety, informed consent, and participant rights.
The Saint John’s Clinical Trials Directory provides information about active and enrolling research studies, including opportunities associated with breast cancer, brain tumors, urologic oncology, thoracic oncology, and other specialties.
Information in a public listing does not guarantee that a patient qualifies or that enrollment remains available. The research team can confirm current study status and eligibility.
Clinical Trials Questions and Contact Information
Patients interested in research participation should begin by discussing available options with their treating physician.
The Saint John’s Cancer Institute clinical research program provides information about studies and general participation requirements.
For current clinical trial inquiries, call 310-582-7448.
Physicians seeking information about research opportunities and trial referrals should use the current Clinical Trials page or contact the clinical research team through the published program number.
Historical research newsletters and individual staff contact information may have changed since the article was originally published in 2023.
Clinical Research, Informed Decisions, and Patient Care
Clinical trials are essential to evaluating new approaches to cancer care, but their value depends on rigorous research, informed consent, and the careful assessment of benefits and risks. Through the original perspectives of Saint John’s Cancer Institute physicians, research professionals, and patient Mark Perzley, this International Clinical Trials Day feature illustrates how research participation contributes to scientific knowledge while remaining a personal medical decision.
Patients and referring physicians can explore Active Clinical Trials at Saint John’s Cancer Institute, review ClinicalTrials.gov, and discuss eligibility with their treating oncology team. For information about clinical trial participation at Saint John’s, call 310-582-7448.
Sources & Further Reading
- Saint John’s Cancer Institute — Active Clinical Trials
- U.S. Food and Drug Administration — Clinical Trial Participation
- National Cancer Institute — What Are Clinical Trials?
- National Cancer Institute — Clinical Trials Search
- ClinicalTrials.gov — Search for Research Studies
- Saint John’s Cancer Institute — Donald L. Morton, MD
- Saint John’s Cancer Institute — Colorectal Cancer Screening Disparities Initiative
